Chemistry:Nilofabicin
From HandWiki
Nilofabicin (CG-400549) is an experimental antibiotic medication related to afabicin, which acts as an inhibitor of the bacterial enzyme enoyl-acyl carrier protein reductase (FabI). It is being researched as a potential treatment for infections by drug-resistant strains of bacteria such as Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa.[1][2][3][4][5]
References
- ↑ "Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor". The Journal of Antimicrobial Chemotherapy 60 (3): 568–74. September 2007. doi:10.1093/jac/dkm236. PMID 17606482.
- ↑ "N-acyl-4-arylaminopiperidines: Design and synthesis of a potential antimicrobial scaffold". Bioorganic & Medicinal Chemistry Letters 112. November 2024. doi:10.1016/j.bmcl.2024.129936. PMID 39214507.
- ↑ "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections". Microbial Biotechnology 16 (7): 1456–1474. July 2023. doi:10.1111/1751-7915.14268. PMID 37178319.
- ↑ "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. October 2023. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.
- ↑ "Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research". Angewandte Chemie. November 2024. doi:10.1002/anie.202414325. PMID 39611429.
 |  |
